BioDuro
- Company typePrivate
- Founded1996
- HeadquartersSan Diego, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
BioDuro firmographics
Firmographics- Name
- BioDuro
- Legal name
- BioDuro
- Website
- https://bioduro-sundia.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
BioDuro industry classification
Industry- Product category
- Contract Research and Manufacturing Services (CRDMO)
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
- akta.pro secondary industries
- DMPK / ADME & Bioanalysis (HLAGAFAC), Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where BioDuro is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BioDuro business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Contract Research Services: BioDuro provides fee-for-service research contracts across discovery chemistry, biology, DMPK, and pharmacology services. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.
- Drug Substance Manufacturing: API development and manufacturing services including kilo and pilot scale production, process R&D, and scale-up synthesis.
- Drug Product Services: Formulation development, preformulation, and drug product manufacturing services including bioavailability enhancement technologies (HME, SDD, amorphous solid dispersion).
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
BioDuro product offering
Product offeringCore offering
BioDuro is a global contract research, development, and manufacturing organization (CRDMO) that delivers integrated drug discovery, preclinical development, drug substance, and formulation services to pharmaceutical and biotechnology clients. Its offerings span medicinal and synthetic chemistry, DMPK, discovery and translational biology, oncology and pharmacology models, process R&D, scale-up API manufacturing, and drug product formulation, bundled with specialized platforms for peptides, PROTACs, ADCs, DNA-encoded libraries, and AI-powered peptide design.
Product overview
BioDuro is a fully integrated contract research, development, and manufacturing organization (CRDMO) offering end-to-end services from drug discovery through commercial manufacturing. The portfolio includes core service modules: Chemistry Services (peptide chemistry, medicinal chemistry, synthetic chemistry, computational chemistry, analytical chemistry, scale up chemistry, FBDD), DMPK Services (in vivo/in vitro PK, bioanalytical, toxicity studies, large molecule bioanalysis), Discovery Biology (assay development, SPR, biologics), Oncology Services (PDX, CDX, syngeneic, humanized models), and Pharmacology Services (immunology, metabolic, neuroscience, respiratory). Drug Substance Services cover process R&D, scale up synthesis, and API manufacturing, while Drug Product Services include formulation development with bioavailability enhancement technologies (HME, SDD, amorphous solid dispersion). Specialized platforms include Antibody-Drug Conjugate, Peptide, PROTAC, Solution Engine, Integrated Drug Discovery, IND Enabling, DNA-Encoded Library, and NASH Mouse Models platforms. The company operates across 7 global campuses with over 2,000 scientists serving 1,500+ active customers.
Differentiator
Problem solved
Functional benefit
Products and services
- Chemistry Services Discovery chemistry services for pharmaceutical and biotech sponsors, covering peptide chemistry, medicinal chemistry, parallel synthesis, computational chemistry, synthetic chemistry, analytical chemistry, scale-up chemistry, and fragment-based drug discovery (FBDD).
- DMPK Services Drug metabolism and pharmacokinetics services including in vivo PK and TK studies, in vitro ADME, bioanalytical services, exploratory toxicity in rodents/dogs/monkeys, and large molecule development and bioanalysis for preclinical programs.
- Discovery Biology Services Discovery biology capabilities for target validation and lead characterization, including assay development, biochemical and cellular assays, ligand binding assays, protein science, surface plasmon resonance (SPR), and biologics.
- Oncology Services Oncology research services including patient-derived xenograft (PDX), cell-derived xenograft (CDX), orthotopic, syngeneic, humanized mouse models, CAR-T and CAR-NK mouse models, ELISA assays, and in vitro assays for oncology drug development.
- Pharmacology Services Pharmacology research covering immunology and inflammation, metabolic diseases including MASH mouse models, respiratory, neuroscience, and safety pharmacology to support preclinical efficacy and safety evaluation.
- Drug Substance Services Drug substance development and manufacturing services including process R&D with flow chemistry, sugar chemistry, peptide chemistry, preparative purification, process safety assessment, scale-up synthesis, and kilo- and pilot-scale API manufacturing.
- Drug Product Services Drug product development and formulation services including preformulation, formulation development with hot melt extrusion (HME), spray dried dispersion (SDD), amorphous solid dispersion, bioavailability enhancement, and modified release technologies.
- Dedicated Peptide Business Unit Integrated peptide drug discovery and development offering that consolidates BioDuro's peptide chemistry, synthesis, DMPK, formulation, and AI-enabled design capabilities (including the Atombeat AI collaboration) under a single dedicated unit for global biopharma partners developing peptide therapeutics.
Quantifiable outcome
- 16 months from hit identification to preclinical candidate selection, synthesizing over 400 compounds
- +2 more outcomes
Companies that use BioDuro
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
BioDuro technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
BioDuro partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and supporting.
- CTI BiotechnologycoreBioDuro formed a strategic partnership with CTI Biotechnology to create an integrated preclinical development platform combining drug discovery through IND submission services. The collaboration merges BioDuro's discovery chemistry, biology, DMPK, pharmacology, and manufacturing capabilities with CTI Biotechnology's GLP toxicology and bioanalytical services. The partners aim to streamline development workflows and accelerate the advancement of innovative therapies for global biotech and pharmaceutical clients.
- Dr. Andrew ThomassupportingBioDuro appointed Dr. Andrew Thomas as scientific advisor. Dr. Thomas previously served as Global Head of Medicinal Chemistry at Roche and brings over three decades of pharmaceutical R&D experience. The appointment is intended to strengthen BioDuro's capabilities in innovative drug discovery.
- Dr. Stevan DjuricsupportingBioDuro appointed Dr. Stevan Djuric as scientific advisor. Dr. Djuric was Vice President of Discovery Chemistry and Technology at AbbVie and brings over three decades of pharmaceutical R&D experience. The appointment is intended to strengthen BioDuro's capabilities in innovative drug discovery and provide strategic guidance.
- Cenra API SolutionscoreBioDuro established a joint venture in Taipei with Taiwanese API manufacturer Cenra API Solutions, integrating Cenra's production facility into its global network. The collaboration aims to provide end-to-end API development and manufacturing services, leveraging Cenra's GMP expertise and extensive regulatory history.
- AtombeatcoreBioDuro and Atombeat announced a strategic collaboration to develop an AI-powered platform for accelerated peptide drug discovery. The platform combines Atombeat's AI-driven design technology—which can explore over one trillion potential peptide compounds—with BioDuro's high-throughput synthesis and testing capabilities to deliver cyclic peptides faster and more cost-effectively. The companies aim to provide the pharmaceutical industry with integrated services for peptide drug development.
Scale indicators6 records
Recent moves9 records
Expansion highlights6 records
BioDuro competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Lonza is a global CDMO with leading small molecule, biologics, and cell & gene therapy manufacturing capabilities. Its small-molecule API, peptide, and drug substance manufacturing services directly overlap with BioDuro's drug substance and peptide chemistry offerings.
- WuXi AppTec: WuXi AppTec is the largest global CRDMO offering end-to-end drug discovery, development, and manufacturing services across small molecules, biologics, and cell & gene therapy. It is a direct functional comparable to BioDuro's integrated CRDMO model and the dominant competitor in the China-anchored CRO/CDMO space.
- IQVIA: IQVIA is a global life sciences services giant spanning R&D solutions, clinical, real-world evidence, and technology. Its R&D Solutions business directly overlaps with BioDuro's discovery, preclinical, and bioanalytical offerings, especially for enterprise pharma clients.
- Catalent: Catalent is a global CDMO specializing in drug formulation, bioavailability enhancement (including HME/SDD), and clinical/commercial drug product manufacturing — areas BioDuro divested to Forma Life Sciences. It is a relevant incumbent comparator for BioDuro's legacy drug product scope.
- Labcorp (Fortrea): Fortrea, spun out from Labcorp, is a major clinical and preclinical CRO offering central lab, DMPK, bioanalytical, and early development services. It competes with BioDuro particularly in DMPK, bioanalytical, and integrated preclinical development work.
- Charles River Laboratories: Charles River is a US-based, large-scale CRO offering discovery and safety assessment, DMPK, and manufacturing services. Its preclinical discovery, DMPK, and biologics capabilities directly compete with BioDuro's chemistry, biology, pharmacology, and safety assessment offerings.
Emerging players
- Sygnature Discovery: Sygnature Discovery is a UK-based CRO specializing in integrated medicinal chemistry, DMPK, and in vitro biology. It is a focused, niche peer comparable to BioDuro's integrated drug discovery and DMPK services, though without BioDuro's manufacturing scale.
Direct peers
- Pharmaron: Pharmaron is a China-headquartered, globally integrated CRDMO providing drug discovery, DMPK, preclinical, and API manufacturing services with significant UK/US and China operations. It competes head-to-head with BioDuro across chemistry, biology, DMPK, and drug substance scales.
- Asymchem Laboratories: Asymchem is a China-based CDMO with strong small-molecule API development and manufacturing capabilities, including peptide and oligonucleotide platforms. It directly overlaps with BioDuro's drug substance, peptide chemistry, and kilo/pilot scale API offerings.
- Frontage Laboratories: Frontage is a US- and China-based CRO/CDMO providing DMPK, bioanalytical, CMC, and drug product services. It is a closely comparable peer to BioDuro given its integrated US-China footprint and DMPK/bioanalytical scale, although Frontage is more bioanalytically focused.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioDuro financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioDuro leadership team
Management profileNumber of profiles
Profiles9 records
BioDuro subsidiaries and ownership
Company hierarchySubsidiaries1 record
BioDuro funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioDuro M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioDuro
What does BioDuro do?
BioDuro is a global contract research, development, and manufacturing organization (CRDMO) that delivers integrated drug discovery, preclinical development, drug substance, and formulation services to pharmaceutical and biotechnology clients. Its offerings span medicinal and synthetic chemistry, DMPK, discovery and translational biology, oncology and pharmacology models, process R&D, scale-up API manufacturing, and drug product formulation, bundled with specialized platforms for peptides, PROTACs, ADCs, DNA-encoded libraries, and AI-powered peptide design.
Is BioDuro a public or private company?
BioDuro is a private company. It is classified as unknown and is currently operating.
When was BioDuro founded?
BioDuro was founded in 1996. It employs 1,001 to 5,000 people.
Where is BioDuro based?
BioDuro is headquartered in San Diego, United States, in the North America region.
How does BioDuro make money?
Three revenue lines are on record. Contract Research Services are the primary driver. The others are drug Substance Manufacturing and drug Product Services.
Who are BioDuro's main competitors?
Broad incumbents on record are Lonza Group, WuXi AppTec, IQVIA, Catalent, Labcorp (Fortrea) and Charles River Laboratories. Sygnature Discovery is listed as an emerging player. Direct peers are Pharmaron, Asymchem Laboratories and Frontage Laboratories.
Does BioDuro have an API?
No public API is recorded for BioDuro.
What industry is BioDuro in?
BioDuro's product category is Contract Research and Manufacturing Services (CRDMO). Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAFAC, DMPK / ADME & Bioanalysis. Its NAICS code is 5417 and its SIC code is 8731.